Australian-based ophthalmic artificial intelligence (AI) company Eyetelligence has appointed Mr Babak Asgari as its new director of business development for Asia-Pacific.
The Melbourne firm has developed AI technology that uses retinal imaging to screen for eye and systemic diseases. The technology is being commercialised in the Australian, New Zealand, European, and Japanese markets.
Bringing more than 15 years of medical device experience and a global commercial leadership background, the company expects Asgari to be an invaluable asset.
The appointment is part of a broader commitment to expand beyond domestic borders.
“With a steadfast commitment to innovation, we are taking our cutting-edge AI powered eye screening technology to international markets, making advanced healthcare accessible to more patients worldwide” the company stated.
Asgari was “thrilled” to join Eyetelligence.
“The technology we offer is truly amazing and potentially life changing,” he said.
“I believe I could not join at a better time and am looking forward to the chance to meet everyone at O=MEGA23 and discuss the opportunity to collaborate and bring cutting edge AI-powered technology to the forefront of healthcare and make a true impact on our patients’ lives.”
More reading
US investor backs Australian AI innovation, Eyetelligence
Artificial intelligence: eyecare’s friend of foe?
Bringing telehealth and artificial intelligence into real-world ophthalmology practice
